Literature DB >> 21115975

DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.

Julia Mohr1, Hanne Helfrich, Maxi Fuge, Eric Eldering, Andreas Bühler, Dirk Winkler, Matthias Volden, Arnon P Kater, Daniel Mertens, Doreen Te Raa, Hartmut Döhner, Stephan Stilgenbauer, Thorsten Zenz.   

Abstract

The DNA damage pathway plays a central role in chemoresistance in chronic lymphocytic leukemia (CLL), as indicated by the prognostic impact of TP53 and ATM loss/mutations. We investigated the function of the p53 axis in primary CLL samples by studying p53 and p21 responses to irradiation by FACS and RT-PCR. We observed a distinct response pattern for most cases with a 17p deletion (n = 16) or a sole TP53 mutation (n = 8), but not all cases with a p53 aberration were detected based on a number of different assays used. Samples with a small clone with a TP53 mutation remained undetected in all assays. Only 1 of 123 cases showed high expression of p53, which is suggestive of p53 aberration without proof of mutation of TP53. Samples with an 11q deletion showed a heterogeneous response, with only 13 of 30 showing an abnormal response based on cutoff. Nevertheless, the overall induction of p53 and p21 was impaired, suggesting a gene-dosage effect for ATM in the 11q-deleted samples. The detectability of p53 defects is influenced by clonal heterogeneity and sample purity. Functional assays of p53 defects will detect a small number of cases not detectable by FISH or TP53 mutational analysis. The clinical utility of functional p53 testing will need to be derived from clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115975     DOI: 10.1182/blood-2010-08-300160

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Risk categories and refractory CLL in the era of chemoimmunotherapy.

Authors:  Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

2.  TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.

Authors:  Barbara Kantorova; Jitka Malcikova; Jana Smardova; Sarka Pavlova; Martin Trbusek; Nikola Tom; Karla Plevova; Boris Tichy; Sim Truong; Eva Diviskova; Jana Kotaskova; Alexandra Oltova; Nancy Patten; Yvona Brychtova; Michael Doubek; Jiri Mayer; Sarka Pospisilova
Journal:  Tumour Biol       Date:  2014-12-20

3.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 4.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

5.  An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.

Authors:  L Worrillow; P Baskaran; M A Care; A Varghese; T Munir; P A Evans; S J O'Connor; A Rawstron; L Hazelwood; R M Tooze; P Hillmen; D J Newton
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

6.  Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer.

Authors:  Pei-Yin Hsu; Hang-Kai Hsu; Xun Lan; Liran Juan; Pearlly S Yan; Jadwiga Labanowska; Nyla Heerema; Tzu-Hung Hsiao; Yu-Chiao Chiu; Yidong Chen; Yunlong Liu; Lang Li; Rong Li; Ian M Thompson; Kenneth P Nephew; Zelton D Sharp; Nameer B Kirma; Victor X Jin; Tim H-M Huang
Journal:  Cancer Cell       Date:  2013-08-12       Impact factor: 31.743

7.  Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.

Authors:  G D te Raa; P D Moerland; A C Leeksma; I A Derks; H Yigittop; N Laddach; M Loden-van Straaten; V Navrkalova; M Trbusek; D M Luijks; T Zenz; A Skowronska; M Hoogendoorn; T Stankovic; M H van Oers; E Eldering; A P Kater
Journal:  Cell Death Dis       Date:  2015-08-06       Impact factor: 8.469

8.  p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia.

Authors:  M J Groves; C E Johnson; J James; A R Prescott; J Cunningham; S Haydock; C Pepper; C Fegan; L Pirrie; N J Westwood; P J Coates; I G Ganley; S Tauro
Journal:  Br J Cancer       Date:  2013-10-03       Impact factor: 7.640

9.  Antileukemic activity of sulforaphane in primary blasts from patients affected by myelo- and lympho-proliferative disorders and in hypoxic conditions.

Authors:  Carmela Fimognari; Eleonora Turrini; Piero Sestili; Cinzia Calcabrini; Giovanni Carulli; Giulia Fontanelli; Martina Rousseau; Giorgio Cantelli-Forti; Patrizia Hrelia
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

10.  Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.

Authors:  Federico Pozzo; Michele Dal Bo; Nadia Peragine; Riccardo Bomben; Antonella Zucchetto; Francesca Rossi; Massimo Degan; Davide Rossi; Annalisa Chiarenza; Alberto Grossi; Francesco Di Raimondo; Francesco Zaja; Gabriele Pozzato; Paola Secchiero; Gianluca Gaidano; Giovanni Del Poeta; Giorgio Zauli; Robin Fo À; Anna Guarini; Valter Gattei
Journal:  J Hematol Oncol       Date:  2013-11-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.